No Benefit of Long-Term Beta-Blockers after MI with Preserved EF: REDUCE AMI Trial
Key Points -Beta blocker therapy in patients with acute MI is the…
TACT2: Chelation therapy with EDTA does not improve cardiovascular outcomes in post-MI patients with diabetes
Key Points: EDTA is a highly effective chelator of the ubiquitous pollutants…
ULTIMATE-DAPT: De-escalating to ticagrelor alone after 1 month reduced bleeding without an increase in ischemic events compared to continuous DAPT through 1 year
Key Points: The optimal time to de-escalate from DAPT to SAPT following…
LIBerate-HR Trial: Lerodalcibep, A Small-Binding Protein Based PCSK9 Inhibitor Administered Monthly Significantly Lowered LDL-C
Key Points - Newer cholesterol guidelines advise lower target values for LDL-C…
BRIDGE-TIMI 73a Trial: Olezarsen significantly reduces triglyceride levels among patients with hypertriglyceridemia and elevated CV risk
Key Points: Olezarsen is an antisense oligonucleotide which targets messenger RNA for…
Mandibular Advancement Device (MAD) Therapy Non-Inferior to CPAP for Blood Pressure Reduction In OSA And High CV Risk: The CRESCENT Trial
Key Points: Hypertension (HTN) guidelines recommend treating obstructive sleep apnea (OSA) in…
Targeting Weight Loss to Personalize the Prevention of Type 2 Diabetes Mellitus
Key Points: There is uncertainty determining who is likely to develop dysglycemia…
AEGIS-II: Apo A-I Infusions Did Not Reduce 90-Day MACE but Trended Towards Reduction in CV Death and MI
Key Points: Post-MI adverse cardiovascular events remain high despite robust evidence-based antiplatelet,…
Self-Expanding Evolut Valve non-inferior to Balloon-Expandable SAPIEN Valve in Severe Aortic Stenosis and Small Aortic Annuli
Key Points: The SMART trial is the first randomized non-inferiority trial to…
A single SC dose of Zilebesiran reduced systolic blood pressure in uncontrolled hypertension: KARDIA-2
Key Points: Zilebesiran is a subcutaneous injectable that targets hepatic angiotensinogen (AGT)…
BE ACTIVE RCT: Financial incentive and gamification strategies borrowed from behavioral economics increased physical activity among adults at elevated ASCVD risk
Key Points: The majority of US adults at elevated risk for ASCVD…
STEP-HFpEF DM TRIAL: Semaglutide improves HF-related symptoms and results in greater weight loss among patients with obesity-related HFpEF and type 2 DM
Key Points: Semaglutide, a glucagon-like peptide-1 (GLP-1) analogue, has previously been shown…
Remote Acute Assessment Of Patients With High Cardiovascular Risk Post-Acute Coronary Syndrome (TELE-ACS)
Key Points: TELE-ACS evaluates the use of telemedicine strategies to reduce hospital…
An “Inclisiran First” Strategy Shows Greater LDL-C Lowering Compared With Usual Care In Patients With ASCVD: The VICTORION-INITIATE Randomized Trial
Key Points: Most patients with atherosclerotic cardiovascular disease (ASCVD) do not achieve…
EMPACT-MI: Empagliflozin did not meet primary endpoint but significantly reduced HF hospitalizations
Key Points: Incident heart failure remains common among patients who experience acute…
Self-monitoring and physician-optimized antihypertensive titration post-partum decreases BP during the first 9 months
Key Points: Up to 1 in 10 women experience a hypertensive disorder…
Novel RNA interference therapeutic Zilebesiran results in dose-dependent sustained BP reduction
Key Points: Uncontrolled hypertension is a major public health concern, and this…
VERVE-101, a novel DNA-base editing medication, results in dose-dependent reductions in blood PCSK9 and LDL-C
Key Points: Despite the advent of PCSK9 inhibitors, the majority of patients…
A multi-level hypertension program improved hypertension control in Nigeria
Key Points: The global burden of hypertension is high and increasing, with…
IMPACTS: A multifaceted implementation significantly improved BP control among low-income patients
Key Points This cluster-randomized trial found that a multifaceted implementation strategy to…